By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
Find Your Internal Culinary expert: Cooking Strategies and Recipes - 2Strength training is crucial after menopause. How to make the most of your workouts
- 3Five killed in Israeli air strikes on tents near Khan Younis, medics say
- 4Figure out How to Use the Experience of a Fender bender Legal counselor for Your Potential benefit
- 5German foreign minister backs abandoning EU's unanimity principle
- The Best Cell phone Brands for Tech Lovers
- Huge solar flare no threat to Artemis 2 astronaut launch to the moon, NASA says
- 'Malcolm in the Middle' reboot releases 1st trailer, reuniting Frankie Muniz and Bryan Cranston: Watch here
- The most effective method to Redesign the Sound Framework in Your Smash 1500.
- Instructions to Choose the Best Material Organization for a Fruitful Rooftop Substitution
- Planet-eating stars hint at Earth's ultimate fate
- Step by step instructions to Open a Lovely Waterway Voyage Insight: Conveniences, Administrations, and Elite Offers
- One spent $20 on candy. Another paid $700 for a custom costume. Here's how Halloween costs stacked up this year.
- When darkness shines: How dark stars could illuminate the early universe
